Metabolic therapy for the treatment of ischemic heart disease: reality and expectations

References

• Taegtmeyer H. Metabolism – the lost child of cardiology. J. Am. Coll. Cardiol.36(4), 1386–1388 (2000).
   PubMedGoogle Scholar
• Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin. Investig. Drugs11(5), 615–629 (2002).
   PubMed Web of Science ®Google Scholar
• Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res.86(5), 580–588 (2000).
   PubMed Web of Science ®Google Scholar
• van der Vusse GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol. Rev.72(4), 881–940 (1992).
   PubMed Web of Science ®Google Scholar
• Gert EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J. Clin. Invest.82(6), 2017–2025 (1988).
   PubMedGoogle Scholar
• van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc. Res.45(2), 279–293 (2000).
   PubMed Web of Science ®Google Scholar
• Hamilton JA. Transport of fatty acids across membranes by the diffusion mechanism. Prostaglandins Leukot. Essent. Fatty Acids60(5–6), 291–297 (1999).
   PubMedGoogle Scholar
• Veerkamp JH, Maatman RG. Cytoplasmic fatty acid-binding proteins, their structure and genes. Prog. Lipid Res.34(1), 17–52 (1995).
   PubMed Web of Science ®Google Scholar
• Glatz JF, van der Vusse GJ. Cellular fatty acid-binding proteins, their function and physiological significance. Prog. Lipid Res.35(3), 243–282 (1996).
   PubMed Web of Science ®Google Scholar
• Koonen DP, Glatz JF, Bonen A, Luiken JJ. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim. Biophys. Acta1736(3), 163–180 (2005).
   PubMed Web of Science ®Google Scholar
• Chabowski A, Gorski J, Calles-Escandon J, Tandon NN, Bonen A. Hypoxia-induced fatty acid transporter translocation increases fatty acid transport and contributes to lipid accumulation in the heart. FEBS Lett.580(15), 3617–3623 (2006).
   PubMedGoogle Scholar
• Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev.85(3), 1093–129 (2005).
   PubMed Web of Science ®Google Scholar
• Sambandam N, Lopaschuk GD. AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog. Lipid Res.42(3), 238–256 (2003).
   PubMed Web of Science ®Google Scholar
• Russell RR 3rd, Bergeron R, Shulman GI, Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol.277(2 Pt 2), H643–H649 (1999).
   PubMed Web of Science ®Google Scholar
• Kodde IF, van der Stok J, Smolenski RT, de Jong JW. Metabolic and genetic regulation of cardiac energy substrate preference. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol.146(1), 26–39 (2006).
   PubMedGoogle Scholar
• Randle PJ. Fuel selection in animals. Biochem. Soc. Trans.14(5), 799–806 (1986).
   PubMedGoogle Scholar
• Stanley WC. Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther.9(Suppl. 1), S31–S45 (2004).
   Google Scholar
• Karmazyn M. The role of the myocardial sodium–hydrogen exchanger in mediating ischemic and reperfusion injury. From amiloride to cariporide. Ann. NY Acad. Sci.874, 326–334 (1999).
   PubMed Web of Science ®Google Scholar
• Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions. Cardiovasc. Res.33(2), 243–257 (1997).
   PubMed Web of Science ®Google Scholar
• Young LH, Russell RR 3rd, Yin R et al. Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. Am. J. Cardiol.83(12A), 25H–30H (1999).
   Google Scholar
• Lopaschuk GD, Stanley WC. Malonyl-CoA decarboxylase inhibition as a novel approach to treat ischemic heart disease. Cardiovasc. Drugs Ther.20(6), 433–439 (2006).
   PubMedGoogle Scholar
• Saddik M, Lopaschuk GD. Myocardial triglyceride turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J. Biol. Chem.267(6), 3825–3831(1992).
   PubMedGoogle Scholar
• Lopaschuk GD, Collins-Nakai R, Olley PM et al. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am. Heart J.128(1), 61–67 (1994).
   PubMedGoogle Scholar
• Dyck JR, Kudo N, Barr AJ, Davies SP, Hardie DG, Lopaschuk GD. Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5-AMP activated protein kinase. Eur. J. Biochem.262(1), 184–190 (1999).
   PubMedGoogle Scholar
• Liu Q, Docherty JC, Rendell JC, Clanachan AS, Lopaschuk GD. High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J. Am. Coll. Cardiol.39(4), 718–725 (2002).
   PubMed Web of Science ®Google Scholar
• Murphy E, Perlman M, London RE, Steenbergen C. Amiloride delays the ischemia-induced rise in cytosolic free calcium. Circ. Res.68(5), 1250–1258 (1991).
   PubMed Web of Science ®Google Scholar
• Sodi-Pallares D, Testelli M, Fishelder F. Effects of an intravenous infusion of a potassium-insulin-glucose solution on the electrocardiographic signs of myocardial infarction. Am. J. Cardiol.9, 166–181 (1962).
   PubMed Web of Science ®Google Scholar
• Gradinac S, Coleman GM, Taegtmeyer H, Sweeney MS, Frazier OH. Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting. Ann. Thorac. Surg.48(4), 484–489 (1989).
   PubMed Web of Science ®Google Scholar
• van Wezel HB. Glucose–insulin-potassium techniques in cardiac surgery, historical overview and future perspectives. Semin. Cardiothorac. Vasc. Anesth.10(3), 224–227 (2006).
   PubMedGoogle Scholar
• Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized, placebo-controlled trials. Circulation96, 1152–1156 (1997).
   PubMed Web of Science ®Google Scholar
• Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation98, 2227–2234 (1998).
   PubMed Web of Science ®Google Scholar
• Janiger JL, Cheng JW. Glucose-insulin-potassium solution for acute myocardial infarction. Ann. Pharmacother.36(6), 1080–1084 (2002).
   PubMedGoogle Scholar
• Jeschke MG, Klein D, Bolder U et al. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology145, 4084–4093 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Diaz R et al. Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction, the CREATE-ECLA randomized controlled trial. JAMA293, 437–446 (2005).
   PubMed Web of Science ®Google Scholar
• Leos CL, Griego JE, Anderson JR. Glucose-insulin-potassium therapy in the era of coronary revascularization. Cardiol. Rev.13(5), 266–270 (2005).
   PubMedGoogle Scholar
• Apstein CS, Opie LH. Glucose-insulin-potassium (GIK) for acute myocardial infarction, a negative study with a positive value. Cardiovasc. Drugs Ther.13(3), 185–189 (1999).
   PubMedGoogle Scholar
• Janiger JL, Cheng JW. Glucose-insulin-potassium solution for acute myocardial infarction. Ann. Pharmacother.36(6), 1080–1084 (2002).
   PubMedGoogle Scholar
• Racey-Burns LA, Burns AH, Summer WR, Shepherd RE. The effect of dichloroacetate on the isolated no flow arrested rat heart. Life Sci.44(26), 2015–2023 (1989).
   PubMedGoogle Scholar
• Mazer CD, Cason BA, Stanley WC, Shnier CB, Wisneski JA, Hickey RF. Dichloroacetate stimulates carbohydrate metabolism but does not improve systolic function in ischemic pig heart. Am. J. Physiol.268(2 Pt 2), H879-H885 (1995).
   Google Scholar
• Wargovich TJ, Macdonald RG, Hill JA, Feldman RL, Stacpoole PW, Pepine CJ. Myocardial metabolic and hemodynamic effects of dichloroacetate in coronary artery disease. Am. J. Cardiol.61, 65–70 (1988).
   PubMed Web of Science ®Google Scholar
• Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. Clin. Cardiol.21(12), 888–892 (1998).
   PubMed Web of Science ®Google Scholar
• Wang P, Lloyd SG, Chatham JC. Impact of high glucose/high insulin and dichloroacetate treatment on carbohydrate oxidation and functional recovery after low-flow ischemia and reperfusion in the isolated perfused rat heart. Circulation111(16), 2066–2072 (2005).
   PubMedGoogle Scholar
• Wolff AA, Rotmensch HH, Stanley WC, Ferrari R. Metabolic approaches to the treatment of ischemic heart disease, the clinicians’ perspective. Heart Fail. Rev.7, 187–203 (2002).
   PubMedGoogle Scholar
• Tilley DG, Rockman HA. Role of β-adrenergic receptor signaling and desensitization in heart failure, new concepts and prospects for treatment. Expert Rev. Cardiovasc. Ther.4(3), 417–432 (2006).
   PubMedGoogle Scholar
• McNamara DM, MacGowan GA, London B. Clinical importance of β-adrenoceptor polymorphisms in cardiovascular disease. Am. J. Pharmacogenomics2(2), 73–78 (2002).
   PubMedGoogle Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET), randomised controlled trial. Lancet362, 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Altschul R, Herman IH. Influence of oxygen inhalation on cholesterol metabolism. Arch. Biochem.51, 308–309 (1954).
   PubMedGoogle Scholar
• Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med. Scand.172, 641–645 (1962).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med.9(3), 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients. Long-term benefits with niacin. J. Am. Coll. Cardiol.81, 1245–1255 (1986).
   Google Scholar
• Carlson LA. Nicotinic acid, the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med.258(2), 94–114 (2005).
   PubMed Web of Science ®Google Scholar
• O’Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br. J. Clin. Pharmacol.33(4), 451–453 (1992).
   PubMed Web of Science ®Google Scholar
• Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem. J.227, 651–660 (1995).
   Google Scholar
• Drake-Holland AJ, Passingham JE. The effect of oxfenicine on cardiac carbohydrate metabolism in intact dogs. Basic Res. Cardiol.78, 19–27 (1983).
   PubMed Web of Science ®Google Scholar
• Kahles H, Schafer W, Lick T, Junggeburth J, Kochsiek K. Changes in myocardial substrate and energy metabolism by S-(4)-hydroxyphenylglycine and an N-(6)-derivative of adenosine. Basic Res. Cardiol.81, 258–266 (1986).
   PubMedGoogle Scholar
• Higgins AJ, Morville M, Burges RA, Gardiner DG, Page MG, Blackburn KJ. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischemia rat heart. Life Sci.27, 963–970 (1980).
   PubMed Web of Science ®Google Scholar
• Burges RA, Gardiner DG, Higgins AJ. Protection of the ischaemic dog heart by oxfenicine. Life Sci.29, 1847–1853 (1981).
   PubMed Web of Science ®Google Scholar
• Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc. Res.59(1), 143–151 (2003).
   PubMedGoogle Scholar
• Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur. Heart J.1, 247–253 (1980).
   PubMedGoogle Scholar
• Vik-Mo H, Mjos OD, Neely JR, Maroko PR, Ribeiro LG. Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium. Am. Heart J.111, 1048–1054 (1986).
   PubMed Web of Science ®Google Scholar
• Hirshleifer I. Perhexiline maleate in the treatment of angina pectoris. Curr. Ther. Res. Clin. Exp.11, 99–105 (1969).
   PubMed Web of Science ®Google Scholar
• Cho YW, Belej M, Aviado DM. Pharmacology of a new antianginal drug, perhexiline. I. Coronary circulation and myocardial metabolism. Chest58(6), 577–581 (1970).
   PubMed Web of Science ®Google Scholar
• Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut25(10), 1057–1064 (1984).
   PubMed Web of Science ®Google Scholar
• Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br. Med. J. (Clin. Res. Ed.)284(6312), 295–299 (1982).
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation81(4), 1260–1270 (1990).
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol.52(2), 273–280 (1996).
   PubMed Web of Science ®Google Scholar
• Lee L, Campbell R, Scheuermann-Freestone M et al. Metabolic modulation with perhexiline in chronic heart failure, a randomized, controlled trial of short-term use of a novel treatment. Circulation112(21), 3280–3288 (2005).
   PubMed Web of Science ®Google Scholar
• Unger SA, Kennedy JA, McFadden-Lewis K, Minerds K, Murphy GA, Horowitz JD. Dissociation between metabolic and efficiency effects of perhexiline in normoxic rat myocardium. J. Cardiovasc. Pharmacol.46(6), 849–855 (2005).
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Kiosoglous AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J. Cardiovasc. Pharmacol.36(6), 794–801 (2000).
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ. Res.63(6), 1036–1043 (1988).
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol. Cell Biochem.88(1–2), 175–179 (1989).
   PubMedGoogle Scholar
• Wall SR, Lopaschuk GD. Glucose oxidation rates in fatty acid-perfused isolated working hearts from diabetic rats. Biochim. Biophys. Acta1006(1), 97–103 (1989).
   PubMed Web of Science ®Google Scholar
• Turcani M, Rupp H. Modification of left ventricular hypertrophy by chronic etomixir treatment. Br. J. Pharmacol.126(2), 501–507 (1999).
   PubMed Web of Science ®Google Scholar
• Zarain-Herzberg A, Rupp H, Elimban V, Dhalla NS. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J.10(11), 1303–1309 (1996).
   PubMed Web of Science ®Google Scholar
• Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am. J. Physiol. Renal Physiol.278, F667–F675 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. (Lond.)99(1), 27–35 (2000).
   PubMed Web of Science ®Google Scholar
• Stanley WC, Morgan EE, Huang H et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am. J. Physiol. Heart Circ. Physiol.289(6), H2304–H2309 (2005).
   PubMed Web of Science ®Google Scholar
• Dyck JR, Hopkins TA, Bonnet S et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation114(16), 1721–1728 (2006).
   PubMed Web of Science ®Google Scholar
• Tang WH. Metabolic approach in heart failure, rethinking how we translate from theory to clinical practice. J. Am. Coll. Cardiol.48(5), 999–1000 (2006).
   PubMedGoogle Scholar
• Fantini E, Demaison L, Sentex E et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J. Mol. Cell Cardiol.26(8), 949–958 (1994).
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Horowitz JD. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc. Drugs Ther.12(4), 359–363 (1998).
   PubMed Web of Science ®Google Scholar
• Lopaschuk GD, Barr R, Thomas PD et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ. Res.93(3), e33–e37 (2003).
   Google Scholar
• Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine, a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br. J. Clin. Pharmacol.37, 279–288 (1994).
   PubMed Web of Science ®Google Scholar
• Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina, a meta-analysis of randomized, double-blind, controlled trials. Coron. Artery Dis.14(2), 171–179 (2003).
   PubMed Web of Science ®Google Scholar
• Chazov EI, Lepakchin VK, Zharova EA et al. Trimetazidine in Angina Combination Therapy – the TACT study, trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am. J. Ther.12(1), 35–42 (2005).
   PubMedGoogle Scholar
• Koylan N, Bilge AK, Adalet K, Mercanoglu F, Buyukozturk K; TTS Group. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol.59(6), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Ruzyllo W, Szwed H, Sadowski Z et al. Efficacy of trimetazidine in patients with recurrent angina, a subgroup analysis of the TRIMPOL II study. Curr. Med. Res. Opin.20(9), 1447–1454 (2004).
   PubMedGoogle Scholar
• Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris, a multicenter, double-blind, placebo-controlled study. Am. J. Cardiovasc. Drugs3(5), 361–369 (2003).
   PubMedGoogle Scholar
• Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst. Rev.19(4), CD003614 (2005).
   Google Scholar
• Simkhovich BZ, Meirena DV, Khagi KhB, Kalvin’sh IIa, Lukevits EIa . Effect of a new structural analog of γ-butyrobetaine-3-(2,2,2-trimethylhydrazine) propionate (THP) on carnitine level, carnitine-dependent fatty acid oxidation and various indices of energy metabolism in the myocardium. Vopr. Med. Khim.32(4), 72–76 (1986).
   PubMedGoogle Scholar
• Simkhovich BZ, Shutenko ZV, Meirena DV et al. 3-(2,2,2-trimethylhydrazinium) propionate (THP) – a novel γ-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem. Pharmacol.37, 195–202 (1988).
   PubMed Web of Science ®Google Scholar
• Sesti C, Simkhovich BZ, Kalvinsh I, Kloner RA. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. J. Cardiovasc. Pharmacol.47(3), 493–499 (2006).
   PubMed Web of Science ®Google Scholar
• Liepinsh E, Vilskersts R, Loca D et al. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in γ-butyrobetaine contents and cardioprotection in isolated rat heart infarction. J. Cardiovasc. Pharmacol.48(6), 314–319 (2006).
   PubMed Web of Science ®Google Scholar
• Teplyakov AT, Sankevitch TV, Stepatcheva TA, Mamchur SE. The use of fatty acid β-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction. Kardiologiia43(12), 15–18 (2003).
   PubMedGoogle Scholar
• Semigolovskii NIu. Use of antihypoxants in the acute period of myocardial infarction. Anesteziol. Reanimatol.2, 56–59 (1998).
   Google Scholar
• McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation93(1), 135–142 (1996).
   PubMed Web of Science ®Google Scholar
• MacInnes A, Fairman DA, Binding P et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res.93(3), e26–e32 (2003).
   PubMed Web of Science ®Google Scholar
• Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between rRanolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J. Pharmacol. Exp. Ther.321(1), 213–220 (2007).
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation110(8), 904–910 (2004).
   PubMed Web of Science ®Google Scholar
• Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur. J. Pharmacol.418(1–2), 105–110 (2001).
   PubMedGoogle Scholar
• Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J. Pharmacol. Exp. Ther.318(1), 418–423 (2006).
   PubMed Web of Science ®Google Scholar
• Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation113(20), 2462–2472 (2006).
   PubMed Web of Science ®Google Scholar